Business
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia
About this update from Bioxcel Therapeutics, Inc.
[{"type":"text","content":"Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by Alzheimer’s agitation, with approximately ~100 million annual episodes1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it will host a virtual key opinion leader (KOL) roundtable on Friday, February 27, from 2:00 to 3:00 p.m. EST. The event is a continuation of the Company’s awareness and educational initiatives focused on addressing acute agitation episodes associated with neuro-psychiatric diseases. The discussion will center on acute agitation episodes in Alzheimer’s dementia, highlighting the large unmet need for treatment options for this patient population and caregivers across a variety of settings. Acute agitation episodes related to Alzheimer’s dementia impacts a substantial patient population, accounting for approximately 100 million episodes annually.1 The panelists will also explore the potential role of BXCL501 as a differentiated treatment option in this disease area. BXCL501 is a late-stage product candidate being evaluated for the treatment of acute agitation episodes in Alzheimer’s dementia. There are no FDA-approved therapies for the treatment of acute agitation episodes in Alzheimer’s dementia. Currently, the Company is advancing preparations for the initiation of the TRANQUILITY In-Care Phase 3 trial, a second double-blind, placebo-controlled study to evaluate BXCL501 for the treatment of acute agitation episodes in Alzheimer's dementia. The roundtable event will be moderated by Anjalee Khemlani, an award-winning healthcare journalist and podcast host (Give It To Me Straight, Doc), known for her in-depth reporting on the industry, most recently at Yahoo Finance. The roundtable will feature the following medical professionals: George T. Grossberg, MD, Inaugural Henry & Amelia Nasrallah Endowed Professor, Director Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience, Saint Louis University School of MedicineAnton P. Porsteinsson, MD, William B...